TearSolutions has landed two FDA designations for Lacripep, a topical synthetic peptide that could become the first targeted treatment for a rare and painful corneal disease. The agency granted both Orphan Drug and Fast Track status. Phase two dosing has already started.

This is the kind of peptide story that gets lost behind GLP-1 headlines. A small biotech. A first-in-class mechanism. A disease with no approved therapy. And a peptide discovered not in a pharma lab but in an academic screen of human tear proteins.

What Lacripep Is and Why It Matters

Lacripep is a synthetic fragment of lacritin, a one-hundred-nineteen-amino-acid protein found naturally in human tears. Researchers at the University of Virginia discovered it through an unbiased screen funded by the National Institutes of Health National Eye Institute. The peptide has a dual mechanism. It promotes nerve repair and it reactivates the eye’s own tear production machinery.

The target indication is neurotrophic keratitis, or NK. In NK, the cornea loses sensitivity. The surface cannot heal itself. Patients develop persistent epithelial defects. Some lose vision. There is no approved drug for this condition in the United States. That explains why the FDA handed out two designations at once.

The Regulatory Path and What Comes Next

Orphan Drug Designation brings tax credits for clinical testing and seven years of market exclusivity upon approval. Fast Track means more frequent FDA meetings and the option for a rolling drug application review. Getting both at the same time is a clear signal. The agency sees an unmet need and wants this program to move.

The phase two trial is now underway. It is a multicenter, randomized, vehicle-controlled study with about fifty-four patients. The trial identifier is NCT07568730. TearSolutions CEO Anil Asrani called the dual designations a significant milestone that validates the company’s approach to transforming NK treatment.

Expert Insight

But what most people miss about topical peptide therapeutics is the formulation challenge. Peptides do not easily cross the corneal epithelium. A peptide that looks active in a dish can be useless in an eye drop if the formulation does not solve the delivery problem. The fact that Lacripep has advanced to phase two with the FDA’s encouragement suggests TearSolutions has cracked something real here.

What experienced teams know is that ophthalmic peptides occupy a strategic sweet spot. The eye is an immune-privileged site. Systemic exposure from a topical drop is minimal. That means safety concerns that derail systemic peptide programs are far less likely. Lacripep may have a cleaner regulatory path than most peptide drugs.

So what does this mean for peptide drug developers watching from the sidelines? One clear lesson is that academic discovery pipelines still produce winning peptide candidates. Lacritin was found in a basic science screen. It was not engineered by a platform company. The field should not overlook publicly funded research as a source of clinical-stage peptides.

The natural question is whether the dry eye disease program will follow. TearSolutions previously told Ophthalmology Times it plans phase two-three trials in dry eye, including in patients with primary Sjogren syndrome. A positive phase two readout in NK would substantially de-risk that larger program. The peptide could address two multi-billion-dollar ophthalmic markets from a single mechanism.

Another question worth asking is about manufacturing. Lacritin-derived peptides are not trivial to produce at scale. The company has not disclosed its synthesis route or CMO partnerships. As the program advances toward registration, manufacturing readiness will become the rate-limiting step. That is a pattern every peptide biotech faces eventually.

Further Reading

• Cenna Nubytide Peptide Takes Aim at Amyloid Production in Alzheimer’s
• Parabilis IPO Validates Intracellular Peptide Technology
• FDA Moves to Reclassify 12 Peptides in Major Regulatory Shift

Last reviewed: June 2026. Peptide Proof Editorial Team. Sources: Ophthalmology Times, TearSolutions Press Release

TearSolutions just landed two FDA designations for Lacripep, a first-in-class synthetic peptide aimed at neurotrophic keratitis. The agency granted both Rare Pediatric Disease and Fast Track status. A Phase 2 trial evaluating safety and efficacy in fifty-four patients has already dosed its first participants.

Neurotrophic keratitis, or NK, is a rare degenerative condition. The corneal nerves stop working. The eye loses its ability to sense damage. The cornea breaks down. There are very few treatment options. A peptide that could reverse the underlying nerve damage would change the standard of care entirely.

What Lacripep Is and How It Works

Lacripep is a synthetic peptide derived from lacritin. Lacritin is a natural tear protein that the eye produces to maintain corneal health. In preclinical work, the peptide did three things. It resolved underlying nerve damage. It reactivated physiological basal tear secretion. And it restored health to the corneal epithelium. Those three effects address the root cause of NK, not just the surface symptoms.

Here’s why this matters. Current NK treatments focus on lubricating the eye surface or closing the tear ducts to retain moisture. They do not repair the nerves. A therapy that actually restores corneal innervation would be the first disease-modifying option for these patients.

The Regulatory Path Forward

The Rare Pediatric Disease designation comes with a voucher. If Lacripep is approved, TearSolutions receives a priority review voucher that it can sell or use for another drug. Those vouchers have traded for over one hundred million dollars in past deals. Fast Track means more frequent meetings with the FDA and eligibility for rolling review and accelerated approval.

These two designations together signal that the FDA sees genuine unmet need in NK. The agency does not hand out both designations lightly. It reserves them for diseases where the current standard of care is genuinely inadequate. That’s exactly the situation with neurotrophic keratitis.

Expert Insight

But what most people miss is the formulation challenge. Eye-drop peptides face a brutal pharmacokinetic problem. The tear film clears the ocular surface within minutes. A peptide has maybe sixty to ninety seconds to penetrate the cornea before it gets washed down the nasolacrimal duct. Most peptide teams underestimate how different ocular delivery is from subcutaneous injection. The peptide that works beautifully in a dish often never reaches the corneal nerves in a patient.

TearSolutions has been working on this for years. The fact that they moved into Phase 2 suggests they solved the residence-time problem. But the real test is whether the Phase 2 efficacy data holds up in a larger population. Neurotrophic keratitis has several subtypes. What works for post-herpetic NK may not work for diabetic NK. Experienced teams know to stratify their patients carefully.

So what does this mean for the broader peptide field? The natural question is whether lacritin-derived peptides could work for other ocular surface diseases. Dry eye disease affects millions of people. If Lacripep proves that a synthetic tear protein peptide can restore corneal health in NK, the same approach could be adapted for moderate to severe dry eye. That’s a much larger market. But the formulation hurdles scale non-linearly with target tissue depth.

Another question readers ask is about the timeline. Fast Track does not mean fast approval. It means faster communication with regulators. A Phase 2 trial in fifty-four patients is designed to find a signal. If the signal is strong, a Phase 3 pivotal trial follows. Realistically, an NDA filing is three to four years away at minimum. But for a rare disease with no disease-modifying therapies, the bar for approval may be lower than for a crowded indication like dry eye.

Further Reading

• Cenna Nubytide Peptide Takes Aim at Amyloid Production in Alzheimer’s
• FDA Moves to Reclassify 12 Peptides in Major Regulatory Shift
• Retatrutide Hits 30% Weight Loss in Pivotal Phase 3 Trial

Last reviewed: June 2026. Peptide Proof Editorial Team. Sources: EyeWorld Weekly, June 5, 2026

The FDA just cleared a peptide drug that could change how we think about treating Alzheimer’s disease. Cenna Biosciences won approval this month to begin human testing of 8M2D, a first-in-class peptide designed to stop amyloid from being made in the first place. The company calls it Nubytide. The first patient should receive it before the year ends.

This is not another plaque-clearing antibody. The three Alzheimer’s drugs approved so far — aducanumab, lecanemab, and donanemab — all work by removing amyloid that has already built up. Nubytide takes a step back. It targets the production line, not the warehouse.

Why Stopping Amyloid Production Matters

Let me break this down. Beta amyloid is a protein fragment that accumulates in the brains of people with Alzheimer’s. For thirty years the dominant theory held that clearing these plaques would slow or stop the disease. But the antibody drugs that do exactly that have delivered modest results at best. Lecanemab slowed cognitive decline by twenty-seven percent in its pivotal trial. That is meaningful. It is also far from a cure.

And the antibodies come with real costs. They require intravenous infusions every two to four weeks. They carry a risk of brain swelling and bleeding called ARIA that requires regular MRI monitoring. The price tags run to twenty-six thousand dollars a year before insurance. These are treatments for people who already show symptoms.

Cenna’s peptide targets the enzyme that produces amyloid, cutting off supply rather than clearing what has already accumulated. If it works, the logic is compelling. The drug is a small peptide, which means it could be cheaper to manufacture than a monoclonal antibody. It could be easier to administer. And because it acts upstream, it could work for prevention — giving it to people at risk before symptoms begin.

The Data Behind the IND Clearance

The numbers tell the story. Fifty-five million people worldwide live with Alzheimer’s or related dementia. That figure grows by two and a half percent each year across the seven largest pharmaceutical markets. Seven point four million patients in the United States alone. One in three seniors dies with the disease.

Cenna has already secured two point seven million dollars from the National Institutes of Health to support early clinical development. The company holds nine issued United States patents and ten international ones. The Phase 1a/1b trial cleared by the FDA will test safety and early signals of efficacy. The company expects proof-of-concept data in twenty twenty-seven or twenty twenty-eight.

“FDA clearance of our IND is a defining milestone for Cenna,” said Nazneen Dewji, the company’s chief executive. “The amyloid-targeting therapies approved to date all work by clearing plaque after it has formed. 8M2D is designed to intervene earlier in the disease process, by stopping amyloid from being produced.”

Expert Insight

But what most people miss is the timing question. Amyloid begins accumulating ten to twenty years before the first symptoms of Alzheimer’s appear. By the time someone walks into a clinic with memory complaints, their brain is already carrying a heavy plaque burden. An antibody that clears existing plaque is treating a late-stage problem. A peptide that stops production could theoretically be given to a fifty-five-year-old with a family history or a positive biomarker test. That is a fundamentally different market and a different clinical development challenge.

Here is the anti-pattern. Biotech companies have been chasing amyloid for decades, and almost all of them have failed. The amyloid hypothesis has more tombstones than success stories. What experienced teams know is that targeting amyloid production — rather than clearance — has its own risks. The beta amyloid precursor protein has normal physiological functions that are still not fully understood. Blocking its processing systemically could have unintended consequences that only human trials will reveal.

So what does this mean for the broader peptide therapeutics field? The natural question is whether peptides can succeed where small molecules and antibodies have struggled in Alzheimer’s. Peptides occupy a middle ground. They are larger than small molecules, which gives them more specificity. They are smaller than antibodies, which makes them cheaper to manufacture and potentially easier to deliver. A peptide that hits an extracellular target like the amyloid-producing enzyme complex, without needing to cross cell membranes or the blood-brain barrier, is playing to the strengths of the modality.

And what about the competitive landscape? Another fair question. Cenna is not alone in seeing opportunity here. Several biotechs are developing peptide and peptidomimetic approaches to neurodegenerative disease. But most are targeting tau or neuroinflammation. Cenna’s direct attack on amyloid production puts it in a lane that is surprisingly uncrowded.

The third question readers will ask is about the timeline. Phase 1 trials take eighteen to twenty-four months. If the data looks good, Phase 2 could begin in twenty twenty-nine, with pivotal data no earlier than the early twenty-thirties. That is a long road. But the Alzheimer’s field moves faster than it used to. The FDA’s accelerated approval pathway, used for both aducanumab and lecanemab, could shorten that timeline if the early efficacy signal is strong enough.

Further Reading

• GLP-1 Weight Loss Drugs Shed 28% Lean Mass — 36-Trial Meta-Analysis
• Peptide Drug Approvals by Modality: What 2020–2026 Data Reveal
• When Will Oral Peptides Replace Injectables? A Realistic Assessment

Last reviewed: June 2026. Peptide Proof Editorial Team. Sources: Cenna Biosciences, Newswire press release (June 17, 2026)

One in eight American adults now takes a GLP-1 drug. That is up from roughly one in fifty just five years ago. The numbers come from Epic Research, which launched a quarterly tracker this June and found that GLP-1 prescriptions climbed from one thousand eight hundred eighty-four per hundred thousand patients in mid-2021 to eight thousand eight hundred nineteen in early 2026. That is a more than fourfold increase, driven almost entirely by semaglutide and tirzepatide.

But just as usage hits this extraordinary peak, new data is exposing what happens when patients stop. And the picture is sobering.

The Rise No One Predicted

When semaglutide won FDA approval for chronic weight management in 2021, few analysts projected the scale of what followed. Tirzepatide followed in 2023. Together they reshaped not just diabetes and obesity care but the entire pharmaceutical landscape. Novo Nordisk and Eli Lilly became two of the most valuable companies on earth. Supply shortages became routine. Compounding pharmacies built entire business lines around GLP-1 copies.

Epic Research now provides hard numbers to quantify the trend. Their data covers more than two hundred million anonymized patient records across the United States. The GLP-1 utilization tracker shows prescriptions growing steadily across both diabetic and non-diabetic populations. The share of U.S. adults classified as obese declined modestly over the same period, from forty-two point three percent to forty point seven percent. That shift represents millions of people moving into a healthier weight category.

So the drugs work. The question now is what happens when people stop taking them.

The WashU Study: Twenty-Two Percent Higher Risk

Researchers at Washington University School of Medicine in St. Louis followed more than three hundred thirty-three thousand U.S. veterans with type 2 diabetes over three years. All had been prescribed GLP-1 drugs. Some continued. Some stopped or interrupted treatment.

The results, published in BMJ Medicine, found that stopping GLP-1 treatment for as little as six months was linked to a significant increase in the risk of major cardiovascular events. Heart attack. Stroke. Death. The longer the treatment gap, the bigger the jump. After two years off GLP-1 drugs, patients faced a twenty-two percent higher risk of major cardiovascular events compared to those who stayed on treatment.

“There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop,” said senior author Ziyad Al-Aly, a WashU Medicine clinical epidemiologist. “Many quit after a few months because of cost, side effects or shortages. When they stop, it is not just weight that comes back. They experience a resurgence in inflammation, blood pressure, and cholesterol. Weight regain is visible. The metabolic reversal is not.”

This is the hidden cost embedded in the GLP-1 revolution. The drugs produce remarkable results but only for as long as people keep taking them. And keeping people on them is proving difficult. A separate study from ScienceDaily found that most people who stop GLP-1 drugs eventually return to them, creating a cycle of stop-start treatment that the WashU data suggests may carry its own cardiovascular penalties.

The Cancer Connection

Amid the cautionary data from WashU, another finding is generating attention. Researchers are now investigating whether GLP-1 drugs may protect against cancer. NPR reported in June that multiple studies have observed lower cancer rates among GLP-1 users, and scientists are working to understand the mechanism. The leading hypothesis involves the drugs’ anti-inflammatory effects and their ability to reduce obesity, a known cancer risk factor.

If confirmed, this would add another layer to the already complex calculus around GLP-1 therapy. The benefits accumulate with continued use. But the WashU study makes clear that these benefits are not permanent. They are rented, not owned.

What Experienced Teams Know

Here is the anti-pattern that most market observers miss. The GLP-1 business model assumes chronic, lifelong therapy. That is what makes the revenue projections work. But real-world adherence data tells a different story. Cost is the number one barrier. At roughly a thousand dollars per month out of pocket for weight loss indications, many patients simply cannot sustain treatment. Side effects drive others away. Supply shortages force interruptions.

The WashU study reveals that these interruptions are not neutral. Each treatment gap creates a window of elevated cardiovascular risk. Over time, the cumulative effect may largely erase the protection gained while on the drug. This has profound implications for how payers, providers, and manufacturers think about GLP-1 access. A therapy that only works when taken continuously is a therapy that demands continuous coverage.

Experienced clinical teams are already adapting. Some are tapering patients to lower maintenance doses rather than stopping entirely. Others are using combination approaches with cheaper generic alternatives to bridge gaps. But these are workarounds, not a systemic solution.

So where does this leave us? The Epic Research data confirms that GLP-1 drugs have achieved mass adoption faster than almost any drug class in history. The WashU data warns that the consequences of interrupted treatment extend well beyond weight regain into life-threatening cardiovascular territory. And the cancer protection research suggests the benefits may be even broader than initially understood.

These three threads together point toward an inevitable conclusion. GLP-1 drugs work. They work for multiple conditions. But they require sustained, uninterrupted access to deliver their full benefit. That access question, more than any single clinical data point, will define the next chapter of the GLP-1 story.

Something to watch.

Further Reading

• Retatrutide Hits 30% Weight Loss in Pivotal Phase 3 Trial
• GLP-1 Weight Loss Drugs Shed 28% Lean Mass — 36-Trial Meta-Analysis
• When Will Oral Peptides Replace Injectables? A Realistic Assessment

Last reviewed: June 2026. Peptide Proof Editorial Team. Sources: Epic Research, WashU Medicine, NPR

Gelteq just took the step that separates peptide science from peptide medicine. The Australian biotech announced it is entering its first human clinical trial. The company also launched a veterinary study program. And it closed a three and a half million dollar financing round to pay for both.

This is not a mega-deal. It is not a billion-dollar acquisition. But for anyone tracking the peptide therapeutics pipeline, Gelteq’s move matters. It represents something rare right now. A new peptide company actually crossing from preclinical promise into human testing.

What Gelteq Actually Does

Gelteq builds its platform around oral peptide delivery. That is the holy grail of peptide therapeutics. Most peptides cannot be taken as pills. They get destroyed in the stomach before they reach the bloodstream. So patients inject them. Semaglutide. Tirzepatide. Insulin. All needles.

Gelteq claims to have solved part of this problem. Their technology aims to protect peptides through the digestive system and deliver them into circulation. If it works at scale, the implications go far beyond one company. Oral peptide delivery would expand the addressable market for every peptide drug on the market and every one in development.

But here is the context that matters. Oral peptide delivery has been the promised land for thirty years. Dozens of companies have tried. Most have failed. The biology is genuinely hard. Peptides are large, fragile molecules. The gut evolved to break them down. Getting meaningful bioavailability from an oral peptide is a physics problem as much as a biology one.

The Data Points

Gelteq’s announcement had three concrete pieces of news. A human clinical trial is now launching for their lead program. A companion veterinary study is running in parallel, targeting the animal health market. And the company raised three point five million dollars in new financing.

The veterinary angle is clever. Animal health has lower regulatory barriers and faster time to market than human therapeutics. A company can generate revenue and clinical validation data from veterinary products while the human trials grind forward. Several peptide companies have used this two-track strategy successfully. It reduces the cash burn between financing rounds.

The three and a half million dollar raise is modest by biotech standards. But in the current funding environment, any financing is a signal. The biotech IPO window has reopened in 2026. Kardigan raised four hundred million dollars last week. Early-stage peptide companies are getting meetings again. Gelteq’s round, however small, confirms that peptide platforms still have investor traction.

What Experienced Teams Know

Here is the anti-pattern that seasoned peptide developers watch for. When a company announces a first human trial, the press release always sounds confident. The science sounds ready. But experienced teams know that the gap between preclinical data and human pharmacokinetics is where oral peptide programs go to die.

In animals, you can control everything. Fasted state. Exact dosing. No confounding medications. In humans, you get variability. Some patients take the pill with food. Some have slower gut motility. Some take proton pump inhibitors that change stomach pH. Bioavailability can swing from fifteen percent to two percent between patients. That variability kills programs.

The common mistake is to celebrate the preclinical data and assume the human data will look similar. It almost never does. The companies that succeed are the ones that expect the first human study to disappoint and design the dose-ranging to find the window where absorption is consistent enough to be clinically useful. The companies that fail are the ones that expected a straight line from mice to humans.

Another thing the data does not tell you. Three and a half million dollars does not fund a full clinical program. That amount covers perhaps six to nine months of burn at a small biotech. Gelteq will need to raise again soon. The quality of the first human data will determine whether the next round comes easily or not at all.

Why This Matters for the Broader Peptide Field

The GLP-1 revolution has changed everything for peptide companies. Five years ago, oral peptide delivery was a niche technology story. Today, every major pharma company wants an oral GLP-1. Novo Nordisk has one in late-stage development. Lilly is working on orforglipron. Pfizer tried and failed with danuglipron. The market for an effective oral peptide is measured in tens of billions of dollars.

Gelteq is not competing with Novo Nordisk. But every company that advances oral peptide technology de-risks the platform for everyone else. Manufacturing learnings. Formulation insights. Regulatory precedents. All of it compounds. The peptide field needs more companies testing oral delivery in humans, not fewer.

Now here is the key data point. The number of oral peptide programs entering the clinic has tripled since 2021. Most of that growth is driven by GLP-1 follow-on programs. But companies like Gelteq, Pinnacle Medicines, and others are proving that oral delivery is not limited to one therapeutic class. If the platform generalizes, the peptide drug market could expand by an order of magnitude.

What This Means in Practice

So what should industry watchers track next? First, the design of Gelteq’s human trial. Is it a food-effect study? A single ascending dose? Those are standard first-in-human designs that prioritize safety and pharmacokinetics. What matters is the bioavailability number. If it clears the double-digit threshold, the program has a chance. If it stays in the low single digits, the platform needs more work.

Second, watch the veterinary data timeline. Animal health studies typically read out faster than human trials. If Gelteq can show efficacy in a veterinary model, that provides independent validation of the oral delivery technology. It also generates revenue, which reduces dilution risk for shareholders.

Something to watch. Gelteq has made it to the starting line. The real race begins now.

Further Reading

• GLP-1 Weight Loss Drugs Shed 28% Lean Mass — 36-Trial Meta-Analysis
• GLP-1/GLP-2 Co-agonists: Multi-Receptor Strategies Reshape Metabolic Drug Development
• Retatrutide Hits 30% Weight Loss in Pivotal Phase 3 Trial

Last reviewed: June 2026. Peptide Proof Editorial Team. Source: Stock Titan, The Manila Times